Efficacy of antiretroviral therapy in Africa: Effect on immunological and virological outcome measures - A meta-analysis

International Journal of STD and AIDS

Volumn 19, Issue 5, 2008, Pages 291-296

  Hammond, Rebecca ^a   Harry, Tubonye C ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b JAMES PAGET UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiretroviral drugs; CD4 count; Meta analysis; Sub Saharan Africa; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VIRUS LOAD;

AFRICA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 44349158953     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2007.007248     Document Type: Review

References (38)

1. World Health Organization. '3 by 5 Strategy'. See [http://www.who.int/3by5/about/initiative/en/index.html] (accessed 13 April 2007)
2. UNAIDS/WHO. Progress in Scaling Up Access to ART in Low and Middle Income Countries June 2006. See [http://www.who.int/hiv/toronto2006/ FS_Treatment_en.pdf] (accessed 13 April 2007)
3. UNAIDS/WHO. AIDS Epidemic Update: December 2006. See [http://www.unaids.org/en/HIV_data/epi2006/default.asp] (accessed 13 April 2007)
4. WHO. Director-General Calls for 'Urgent Treatment' for People with AIDS in Africa. See [http://www.who.int/mediacentre/news/releases/2003/pr65/ en/index.html] (accessed 13 April 2007)
5. HIV/AIDS programme. Towards Universal Access. WHO Advocacy Report. World Health Organization. See [http://www.who.int/hiv/universalaccess2010/ en/index.html] (accessed 13 April 2007)
6. Danel C, Moh R, Anzian A, et al. Tolerance and acceptability of an efavirenz based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006;42:29-35
7. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001;358:410-4
8. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002;16:1139-46
9. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005;41:217-24
10. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003;17(suppl. 3):S5-15
11. Laurent C, Diakhate N, Gueye NFN, et al. The Seneglese government's highly active antiretroviral therapy initiative: an 18-month follow up study. AIDS 2002;16:1363-70
12. Laurent C, Ngom Gueye NF, Ndour CT, et al. ANRS 1215/1290 study group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005;38:14-7
13. Spaecek LA, Shihab HM, Kamya MR, Mweisigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2005;34:979-86
14. van Oosterhout JJ, Bodasin N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005;10:464-70
15. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patient's response, survival and drug resistance. Lancet 1002;360:34-40
16. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005;40:336-43
17. Macharia DK, Chang LW, Lule G, et al. Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians. AIDS 2003;17:938-9
18. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;302:867-72
19. Bourgeois A, Laurent C, Mougnutou R, et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther 2005;10:335-41
20. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006;367:1335-42
21. Habtegiorgis A, Gebreyesus S, Mulugeta E. Evaluation of antiretroviral treatment in two private medical centres in Addis, Ethiopia. Ethiop Med J 2003;41:345-51
22. Greenhalgh T. How to read a paper: getting your bearings (deciding what the paper is about). BMJ 1997;315:243-6
23. Fischer A, Karasi JC, Kibibi D, et al. Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002. HIV Med 2006;7:64-6
24. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 count of 200 cubic millimetres or less. N Engl J Med 1997;337:725-33
25. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004;18(suppl 3):S27-31
26. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368:505-10
27. Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006;20:1613-9
28. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-9
29. Fethi T, Asma J, Amine SM, et al. Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings. Curr HIV Res 2006;3:271-6
30. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses 2002;18:1181-7
31. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364:29-34
32. Livesley N, Morris C. Antiretroviral therapy in a primary care clinic in rural South Africa. AIDS 2003;17:2005-6
33. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004;20:1053-6
34. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003;17:1369-75
35. Oyugi JH, Byakika-Tusiime J, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004;36:1100-2
36. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. ANRS 1203 Study Group. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Coted'Ivoire. Antiviral Ther 2003;8:385-93
37. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia. J Am Med Assoc 2006;296:782-93
38. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006;20:41-8